A six month double-blind, placebo-controlled trial followed by a six month open-label study of the early administration of alendronate [alendronic acid] on prevention of bone loss after hip fracture

Trial Profile

A six month double-blind, placebo-controlled trial followed by a six month open-label study of the early administration of alendronate [alendronic acid] on prevention of bone loss after hip fracture

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top